ClinicalTrials.gg
RecruitingNCT07116434Updated Dec 23, 2025

Discovery Diabetes

An interventional study of Discovery Program in Type 1 Diabetes, sponsored by Vanderbilt University Medical Center. Recruiting at 1 site in United States. Open to participants aged 13 Years to 21 Years. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by Vanderbilt University Medical Center · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
13 Years to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Diabetes Mellitus, Type 1 by Vanderbilt University Medical Center — 5 open to participants now, 6 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Vanderbilt University Medical Center.

Planned enrollment
3rd of 14
150 · median 50
Started
2025
with 2 others
No phase
11 of 15
3 open now
Registered
15th of 15
by date

Among the 15 studies in Diabetes Mellitus, Type 1 by Vanderbilt University Medical Center, this one is the 3rd largest by planned enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2025, is one of 11 with no phase, and was the 15th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

5 of the 15 studies in Diabetes Mellitus, Type 1 by Vanderbilt University Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 13 Years to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Diabetes Mellitus, Type 1 by Vanderbilt University Medical Center, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if the Discovery Program can help improve diabetes management in adolescents and young adults with type 1 diabetes (T1D). The main questions it aims to answer are:

Does the Discovery Program lead to better glycemic control as measured by HbA1c levels? How does participation in the Discovery Program affect diabetes distress and self-management skills? Researchers will compare participants in the Discovery Program to those receiving standard diabetes care to see if the program has a positive effect on diabetes management.

Participants will:

Engage in a 3-month intervention that includes personalized mobile health communications and clinician support.

Complete surveys and assessments at the beginning of the study, and again at 3 and 6 months.

Allow the study team to access their electronic health records for additional data on diabetes management.

Read the detailed description

The Discovery Diabetes study is a pilot randomized controlled trial designed to evaluate the effectiveness of the Discovery Program in improving diabetes management among adolescents and young adults with type 1 diabetes (T1D). This study focuses on participants aged 13 to 21 who have been diagnosed with T1D for at least one year.

Study Design: Participants will be randomly assigned to either the intervention group, which will receive the Discovery Program, or a control group receiving standard diabetes care. The Discovery Program includes personalized mobile health communications, clinician support, and structured problem-solving sessions aimed at addressing psychosocial barriers to effective diabetes management.

Objectives: The primary objective is to determine whether the Discovery Program leads to significant improvements in glycemic control, measured by changes in HbA1c levels over a 6-month period. Secondary objectives include assessing the impact on diabetes distress, self-management behaviors, and participants' problem-solving skills.

Data Collection: Data will be collected at baseline, 3 months, and 6 months, utilizing a variety of methods, including surveys and electronic health records (EHR). The study will ensure participant confidentiality through the use of unique study IDs and secure, HIPAA-compliant data storage systems, such as REDCap.

Eligibility Criteria: Eligible participants include those aged 13-21 with a diagnosis of type 1 diabetes, while individuals with type 2 diabetes or other conditions that may hinder participation will be excluded.

Retention and Use of Data: All collected data will be retained for at least six years post-study completion, in compliance with institutional and regulatory requirements. De-identified data may be used for research publications or presentations, ensuring participant privacy is maintained throughout the study.

This trial aims to provide valuable insights into improving diabetes management strategies for young individuals facing unique challenges in their care.

03

Conditions studied

  • Type 1 Diabetes
04

Who can participate

Ages eligible
13 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adolescents (13-17 years) and young adults (aged 18-21 years),
  • Diagnosed with T1D for at least one year,
  • Access to a smartphone,
  • A My Health at Vanderbilt (MHAV) patient portal account,
  • Ability to read, speak, and understand English,
  • An appointment with an NP in the VUMC Eskind Clinic within 7 months of initial contact

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of type 2 diabetes
  • Any physical, cognitive, sensory or emotional condition precluding participation in the intervention (seeing/using a phone, hearing digital stories, answering questions).
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Intervention Group: Discovery Program

    This arm will receive the Discovery Program intervention, which includes personalized mobile health communications and clinician support aimed at improving diabetes management.

    Behavioral: Discovery Program

  • No intervention
    Control Group: Standard Diabetes Care

    This arm will continue with standard diabetes care practices without the additional psychosocial intervention provided to the intervention group.

Interventions

  • BehavioralDiscovery Program

    The Discovery Program is a novel, hybrid intervention specifically designed to address the psychosocial barriers faced by adolescents and young adults with T1D. This intervention integrates three key components: 1. Patient-Reported Measures 2. In-Clinic Collaborative Goal Setting 3. Personalized Mobile Health Communications The Discovery Program will be delivered over a 3-month intervention period, followed by a 6-month follow-up to assess outcomes. This approach not only aims to improve glycemic control but also seeks to enhance diabetes self-management behaviors, reduce diabetes distress, and build problem-solving skills among participants. The integration of clinical informatics, personalized support, and mobile health technology distinguishes this intervention from traditional diabetes care practices, which often overlook psychosocial factors affecting health outcomes.

06

What researchers measure

Primary outcomes

  1. Change in Glycemic Control (HbA1c)

    This outcome measure will assess the change in glycemic control among participants, as indicated by changes in HbA1c levels. The primary aim is to determine whether the Discovery Program leads to significant improvements in glycemic control compared to standard diabetes care.

    Time frame: Baseline, 3 months, 6 months, and 9 months

Secondary outcomes

  1. Change in Diabetes Distress (PAID-T)

    This measure will evaluate changes in diabetes distress using the Problem Areas in Diabetes - Teen version (PAID-T) to assess participants' emotional responses related to diabetes management. Each item is scored on a Likert-type scale, from 1 (not a problem) to 6 (serious problem). Scores are summed and then transformed to a 0-100 scale. Minimum value: 0 (no distress), Maximum value: 100 (high distress). Higher scores indicate worse outcomes, meaning more diabetes-related emotional distress.

    Time frame: Baseline, 3 months, and 6 months

  2. Change in Self-Management Barriers (BDA)

    This outcome will assess changes in barriers to diabetes self-management through the Barriers to Adherence Scale (BDA), focusing on factors that may hinder effective diabetes care. The BDA uses a 23-item self-report format where each statement is rated on a 5-point Likert-type scale: 1 = Not at all true and 5 = Completely true. There are 5 distinct subscales which are measured: Stress and Burnout, Time Pressure and Planning, Social Support, Parental Autonomy Support and Stigma. Higher scores reflect greater perceived barriers to diabetes adherence, meaning more challenges experienced by adolescents in managing their condition

    Time frame: Baseline, 3 months, and 6 months.

  3. Change in Problem-Solving Skills (SPSI-R:SF)

    This measure will evaluate changes in problem-solving skills using the Social Problem-Solving Inventory-Revised, Short-Form (SPSI-R:SF, 25-item), which assesses participants' ability to effectively resolve issues related to diabetes management. Each item is scored 0-4 (0 = Not at all true of me; 4 = Extremely true of me). With 25 items, the minimum total score is 0 and the maximum total score is 100. Higher scores on adaptive subscales (Positive Problem Orientation, Rational Problem Solving) = better outcomes. Higher scores on maladaptive subscales (Negative Problem Orientation, Impulsivity/Carelessness Style, Avoidance Style) = worse outcomes. When an overall score is reported, higher values reflect better overall problem-solving ability (maladaptive subscales are reverse-scored for the total).

    Time frame: Baseline, 3 months, and 6 months.

  4. Change in Diabetes Self-Management Efficacy (SCI-R)

    This outcome will assess changes in diabetes self-management efficacy using the Self-Care Inventory-Revised (SCI-R), which measures participants' confidence in managing their diabetes.

    Time frame: Baseline, 3 months, and 6 months.

  5. Change in Glycemic Control (Time in Range)

    This measure will explore changes in the percentage of time participants spend within the target glucose range (TIR) as recorded by Continuous Glucose Monitoring (CGM) devices. Approximately 70% of participants are expected to use CGM devices throughout the study.

    Time frame: Baseline, 3 months, 6 months, and 9 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Nov 2026, 12 months after the start.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 12 months is below that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2025
First posted
Aug 11, 2025
StartActual
Nov 14, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2027
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07116434
Responsible party
Shelagh Mulvaney (Principal Investigator, Vanderbilt University) — Principal investigator
First posted
Aug 11, 2025
Start date
Nov 14, 2025
Primary completion
Nov 2026 (estimated)
Completion
Nov 2027 (estimated)
Last update
Dec 23, 2025

Study contacts

Abigail Doyle, MSHI
Contact
abigail.m.doyle@vanderbilt.edu
615-343-6075
Dina Bu, BS
Contact
dina.bu@vumc.org
Shelagh A Mulvaney, PhD
principal investigator · Vanderbilt University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion